Histopathology of vascular injury in Sprague-Dawley rats treated with phosphodiesterase IV Inhibitor SCH 351591 or SCH 534385

Toxicologic Pathology

Volumn 36, Issue 6, 2008, Pages 827-839

  Zhang, Jun ^a   Snyder, Ronald D ^b   Herman, Eugene H ^a   Knapton, Alan ^a   Honchel, Ronald ^a   Miller, Terry ^a   Espandiari, Parvaneh ^a   Goodsaid, Federico M ^a   Rosenblum, Irwin Y ^c   Hanig, Joseph P ^a   Sistare, Frank D ^b   Weaver, James L ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Kyowa Pharmaceutical Inc   (United States)

Author keywords

Activation and degranulation of mast cell; Activation of endothelial cell and macrophage; Apoptosis of endothelial and smooth muscle cells; Arterial hemorrhage and necrosis; Nitrotyrosine; Peroxynitrite

Indexed keywords

3 NITROTYROSINE; BIOLOGICAL MARKER; CD63 ANTIGEN; FIBRIN; N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE; PHOSPHODIESTERASE IV INHIBITOR; SCH 534385; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD VESSEL INJURY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; FIBRIN DEPOSITION; HISTOPATHOLOGY; IMMUNOREACTIVITY; IMMUNOTOXICITY; MESENTERY BLOOD VESSEL; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; VASCULAR NECROSIS;

ANIMALS; BLOOD VESSELS; CYCLIC N-OXIDES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; IMMUNOHISTOCHEMISTRY; INTESTINE, SMALL; KIDNEY; MESENTERIC ARTERIES; PANCREAS; PHOSPHODIESTERASE INHIBITORS; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; STATISTICS, NONPARAMETRIC; STOMACH; VASCULAR DISEASES;

RATTUS;

EID: 54949120948     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623308322308     Document Type: Article

References (46)

1. Bach, FH, WW Hancock, and C Ferran (1997). Protective genes expressed in endothelial cells: A regulatory response to injury. Immunol Today, 18, 483-86.
2. Ballermann, BJ (1998). Endothelial cell activation. Kidney Int, 53, 1810-26.
3. Boesiger, J, M Tsai, M Maurer, M Yamaguchi, LF Brown, KP Claffey, HF Dvorak, and SJ Galli (1998). Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of Fc receptor expression. J Exp Med, 188, 1135-45.
4. Boros, M, S Takachi, J Masuda, GFJ Newlands, and K Hatanaka (1995). Response of mucosal mast cells to intestinal ischemia-reperfusion injury in the rat. Shock, 3, 125-31.
5. Cotran, RS (1989). Endothelial cells. In Kelly's Textbook of Rheumatology. In S Ruddy, ED Harris, Jr and CB Sledge (Eds.), Vol. 1 (pp. 389-415). Philadelphia: W. B. Sanders.
6. Daguès, N, V Pawlowski, C Sobry, G Hanton, F Borde, S Soler, JL Freslon, and S Chevalier (2007). Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker. Toxicol Sci, 100, 238-47.
7. Daguès, N, V Pawlowski, G Guigon, D Ledieu, C Sobry, G Hanton, JL Freslon, and S Chevalier (2007). Altered gene expression in rat mesenteric tissue following in vivoexposure to a phosphodiesterase 4 inhibitor. Toxicol Appl Pharmacol, 218, 52-63.
8. Denicola, A, and R Radi (2005). Peroxynitrite and drug-dependent toxicity. Toxicology, 208, 273-88.
9. Dent, G, and MA Giembycz (1996). Interaction of PDE 4 inhibitors with enzymes and cell functions. In C Schudt, G Dent and KF Rabe (Eds.), Phosphodiesterase Inhibitors (pp. 111-26). New York: Academic Press.
10. Dickhout, JG, GS Hossain, LM Pozza, J Zhou, S Lhotak, and RC Austin (2005). Peroxynitrite causes endoplasmic reticulum stress and apoptosis in human vascular endothelium: Implications in atherogenesis. Arterioscler Thromb Vasc Biol, 25, 2623-29.
11. Dietsch, GN, CR DiPalma, RJ Eyre, TQ Pham, KM Poole, NB Pefaur, WD Welch, E Trueblood, WD Kerns, and ST Kanaly (2006). Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity. Toxicol Pathol, 34, 39-51.
12. Dvorak, HF, LF Brown, M Detmar, and AM Dvorak (1995). Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol, 146, 1029-39.
13. Frossard, N, Y Landry, G Pauli, and M Ruckstuhl (1981). Effects of cyclic AMP- and cyclic GMP-phosphodiesterase inhibitor on immunological release of histamine and on lung contraction. Br J Pharmac, 73, 933-38.
14. Hanton, G, J-L Le Net, B Ruty, and B Leblanc (1995). Characterization of the arteritis induced by infusion of rats with UK-61,260, an inodilator, for 24 h. Arch Toxicol, 69, 698-704.
15. Ikegami, H, S Kajikawa, K Ito, A Nii, H Okamiya, H Nakayama, and K Doi (2002). Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-β1 (TGF-β1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators. Exp Toxic Pathol, 54, 1-7.
16. Ishii, A, Y Sakai, and A Nakamura (2007). Molecular pathological evaluation of clusterin in a rat model of unilateral ureteral obstruction as a possible biomarker of nephrotoxicity. Toxicol Pathol, 35, 376-82.
17. Jung, K, K, X Liu, W, R Chirco, R Fridman, and HR Kim (2006). Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J, 25, 3934-42.
18. Kerns, W, L Schwartz, K Blanchard, S Burchiel, D Essayan, E Fung, R Johnson, M Lawton, C Louden, J MacGregor, F Miller, P Nagarkatti, D Robertson, F Sistare, P Snyder, H Thomas, B Wagner, A Ward, and J Zhang Expert Working Group on Drug-Induced Vascular Injury (2005). Drug-induced vascular injury: a quest for bio-markers. Toxicol Appl Pharmacol, 203, 62-87.
19. Larson, JL, MV Pino, LE Geiger, and CR Simeone (1996). The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol, 78, 44-49.
20. Li, J, W Li, J Su, W Liu, BT Altura, and BM Altura (2004). Peroxynitrite induces apoptosis in rat aortic smooth muscle cells: Possible relation to vascular diseases. Exp Biol Med, 229, 264-69.
21. Losco, PE, EW Evans, SA Barat, PE Blackshear, L Reyderman, JS Fine, LA Bober, JC Anthes, EJ Mirro, and FM Cuss (2004). The toxicity of SCH 351591, a novel phosphodiesterase 4 inhibitor, in Cynomolgus monkeys. Toxicol Pathol, 32, 295-308.
22. Lyoumi, S, F Tamion, J Petit, P Dehelotte, C Dauguet, M Scotte, M Hiron, A Leplingard, JP Salier, M Daveau, and JP Lebreton (1998). Induction and modulation of acute-phase responses by protein malnutrition in rats: Comparative effect of systemic and localized inflammation on interleukin-6 and acute-phase protein synthesis. J Nutr, 128, 166-74.
23. Mecklenburg, L, A Heuser, T Juengling, M Kohler, R Foell, D Ockert, K Tuch, and G Bode (2006). Mesenteritis precedes vasculitis in the rat mesentery after subacute administration of a phosphodiesterase type 4 inhibitor. Toxicol Lett, 163, 54-64.
24. Mihm, MJ, L Jing, and JA Bauer (2000). Nitrotyrosine causes selective vascular endothelial dysfunction and DNA damage. J Cardiovasc Pharmacol, 36, 182-87.
25. National Research Council (1996). Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press.
26. Nishikata, H, C Oliver, SE Mergenhagen, and RP Siraganian (1992). The mast cell antigen AD1 (homologue to human CD63 or melanoma antigen ME491) is expressed in other cells in culture. J Immunol, 149, 862-70.
27. Pacher, P, JS Beckman, and L Liaudet (2007). Nitric oxide and peroxynitrite in health and disease. Physiol Rev, 87, 315-424.
28. Pruett, SB, R Fan, LP Myers, WJ Wu, and S Collier (2000). Quantitative analysis of the neuroendocrine-immune axis: linear modeling of the effects of exogenous corticosterone and restraint stress on lymphocyte subpopulations in the spleen and thymus in female B6C3F1 mice. Brain Behav Immun, 14, 270-87.
29. Qu, Z, JM Liebler, MR Powers, PT Galey, P Ahmadi, XN Huang, JC Ansel, JH Butterfield, SR Planck, and JT Rosenbaum (1995). Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol, 147, 564-73.
30. Qu, Z, RJ Kayton, P Ahmadi, JM Liebler, MR Powers, SR Planck, and JT Rosenbaum (1998). Ultrastructural immunolocalization of basic fibroblast growth factor in mast cell secretory granules: Morphological evidence for bFGF release through degranulation. J Histochem Cytochem, 46, 1119-28.
31. Robertson, DG, MD Reily, M Albassam, and LA Dethloff (2001). Metabonomic assessment of vasculitis in rats. Cardiovasc Toxicol, 1, 7-19.
32. Shichijo, M, N Inagaki, N Nakai, M Kimata, T Nakahata, I Serizawa, Y Iikura, H Saito, and H Nagai (1998). The effects of anti-asthma drugs on mediator release from cultured human mast cells. Clin Exp Allergy, 28, 1228-36.
33. Slim, RM, DG Robertson, M Albassam, MD Reily, L Robosky, and LA Dethloff (2002). Effect of dexamethasone on the metabonomics profiles associated with phosphodiesterase inhibitor-induced vascular lesions in rats. Toxicol Appl Pharmacol, 183, 108-16.
34. Slim, RM, Y Song, M Albassam, and LA Dethloff (2003). Apoptosis and nitrative stress associated with phosphodiesterase inhibitor-induced mesenteric vasculitis in rats. Toxic Pathol, 31, 638-45.
35. Sohn, HY, F Krotz, A Zahler, T Gloe, M Keller, K Theisen, TM Schiele, V Klauss, and U Pohl (2003). Crucial role of local peroxynitrite formation in neutrophil-induced endothelial cell activation. Cardiovasc Res, 57, 804-15.
36. Souness, JE, D Aldous, and C Sargent (2000). Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology, 47, 127-62.
37. Thompson, WJ, T Ashikaga, JJ Kelly, L Liu, B Zhu, L Vemavarapu, and SJ Strada (2002). regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4). Biochem Pharmacol, 63, 797-807.
38. Torphy, TJ, and BJ Undem (1991). Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax, 46, 512-23.
39. Underwood, DC, JK Matthews, RR Osborn, S Bochnowicz, and TJ Torphy (1997). The influence of endogenous catecholamines on the inhibitory effects of rolipram against early- and late-phase response to antigen in the Guinea pig. J Pharmacol Exp Ther, 280, 210-19.
40. Viera, L, YZ Ye, AG Estevez, and JS Beckman (1999). Immunohisto-chemical methods to detect nitrotyrosine. Methods Enzymol, 301, 373-81.
41. Weaver, JL, R Snyder, A Knapton, EH Herman, R Honchel, T Miller, P Espandiari, R Smith, Y-Z Gu, FM Goodsaid, IY Rosenblum, FD Sistare, J Zhang, and J Hanig (2008). Biomarkers in peripheral blood associated with vascular injury in Sprague-Dawley rats treated with the phosphodiesterase IV inhibitors SCH 351591 or SCH 594385. Toxicol Pathol, 36, 840-849.
42. Weston, MC, N Anderson, and PT Peachell (1997). Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function. Br J Pharmacol, 121, 287-95.
43. Zhang, J, EH Herman, A Knapton, DP Chadwick, VE Whitehurst, JE Koerner, T Papoian, VJ Ferrans, and FD Sistare (2002). SK&F 95654-induced acute cardiovascular toxicity in Sprague-Dawley rats: Histopathologic, electron microscopic, and immunohistochemical studies. Toxicol Pathol, 30, 28-40.
44. Zhang, J, EH Herman, DG Robertson, MD Reily, A Knapton, HV Ratajczak, N Rifai, R Honchel, KT Blanchard, RE Stoll, and FD Sistare (2006). Mechanisms and biomarkers of cardiovascular injury induced by phosphodiesterase inhibitor III SK&F 957654 in the spontaneously hypertensive rat. Toxicol Pathol, 34, 152-63.
45. Zhao, S, Y Zhang, Y Gu, DF Lewis, and Y Wang (2004). Heme oxygenase-1 mediates up-regulation of adhesion molecule expression induced by peroxynitrite in endothelial cells. J Soc Gynecol Investig, 11, 465-71.
46. Zouki, C, SL Zhang, JS Chan, and JG Filep (2001). Peroxynitrite induces integrin-dependent adhesion of human neutrophils to endothelial cells via activation of the Raf-1/MEK/Erk pathway. FASEB J, 15, 25-27.